
WO 02/24235 PCT/EP01/05483

13

CLAIMS

1. Polyazamacrocyclic compounds for radiometal labeling, comprising an N_n system, wherein n is 4, 5 or 6, 5 with varying ring size, and wherein at least one of the N atoms is substituted with a free carboxylate group for coupling to an amino function in a bioactive effector molecule, while all N atoms carry a protected sidechain.

2. Compound as claimed in claim 1 having the 10 general formula:



15


20

3. Compound as claimed in claim 1 or 2, which compound is 1-(1-carboxy-3-carbotertbutoxypropyl)-4,7,10(carbotertbutoxymethyl)-1,4,7,10-

25 tetraazacyclododecane (DOTAGA(tBu)4).

4. Chelating compounds for labeling bioactive molecules with a radiometal, having the general formula:





35

in which:

both Y groups may be positioned either trans as shown or cis;

A is an effector molecule, such as a peptide, in particular octreotide, CCK, substance P, gastrine, a protein, in particular an antibody or enzyme, sugars or radiosensitizing agents, like doxorubicin;

5 R is a hydrogen, a C_1-C_3 alkyl or a alcohol; X is a spacer, in particular $(CH_2)_n-X^*$, in which n is 1-10 and X' is COOH, NH_2 , SH, OH or O-halogen, in which halogen is in particular Br, I or Cl or a molecule of the formula

10 CH_2 -COOH NH_2 -CH $_2$ -COOH CH_2 -COOH

or of the formula

CH₂-NH₂
HOOC-CH₂-CH₂
CH₂-NH₂

Y is COO, CH2CONH2, CH2CH2OH, optionally complexed with a radiometal.

- 5. Compounds as claimed in claim 4, wherein R is hydrogen, n is 1, X' is COOH, Y is COO and A is as defined in claim 3.
- 6. Compound as claimed in claim 5, wherein R is hydrogen, n is 1, X' is COOH, Y is COO and A is octreotide or octreotate.
 - 7. Compound as claimed in claim 4, wherein R is COOH, n is 1, X' is COOH, Y is COO and A is as defined in claim 3.
- 8. Compound as claimed in claim 7, wherein R is 30 COOH, n is 1, X' is COOH, Y is COO and A is octreotide or octreotate.
 - 9. Compounds as claimed in claim 4, selected from the group consisting of DOTAtyr³octreotide, DOTAtyr³octreotate, DOTA3tyr³octreotide,
- 35 DOTA3tyr3octreotate, DOTAt3tyr3octreotide, DOTAta.13tyr3octreotate.

WO 02/24235 PCT/EP01/05483

15

- 10. Use of compounds as claimed in claims 1-3 for the preparation of compounds as claimed in claims 4-9.
- 11. Method for the preparation of radiometal 5 labeled bioactive molecules, comprising the steps of:
 - a) synthesizing compounds as claimed in claims 1-3 having protected side chains on the N atoms and a free carboxylate group;
- b) coupling a bioactive molecule to the free 10 carboxylate group;
 - c) deprotecting the protected side chains; and
 - d) labeling the chelator structure thus obtained with a desired radiometal.
- 12. Compounds as claimed in claims, 4-9 labeled 15 with a radiometal for use in diagnosis and therapy.
 - 13. Use of compounds as claimed in claims 4-9 labeled with a radiometal for the preparation of a diagnostic or therapeutical composition for treatment of various diseases.
- 14. Use as claimed in claim 13, wherein the radiometal label is 90 Y.